Latest Articles

Publication Date
Hormonal Dysregulation and Neuroinflammation in Endometriosis: Convergent Druggable Pathways.

Endometriosis is a chronic, estrogen-dependent disorder defined by ectopic endometrial-like tissue growth, persistent inflammation, and aberrant innervation. Emerging evidence indicates that disease progression and symptom severity are driven by a …

Published: May 19, 2026, midnight
Turning Challenges into Success: Successful Pregnancy in Advanced Maternal Age with Adenomyosis Using Prolonged GnRH Agonist Protocol: A Case Report.

Advanced maternal age (AMA) is a major challenge in reproductive medicine, compounded by coexisting conditions such as adenomyosis and endometriosis, which impair oocyte competence and endometrial receptivity. Prolonged gonadotropin-releasing hormone …

Published: May 19, 2026, midnight
Merck's Sac-TMT Shows Promise in Advanced Endometrial Cancer Tri - GuruFocus

Merck's Sac-TMT Shows Promise in Advanced Endometrial Cancer Tri GuruFocus

Published: May 18, 2026, 11:38 p.m.
Merck (MRK) Achieves Milestone in Endometrial Cancer Treatment T - GuruFocus

Merck (MRK) Achieves Milestone in Endometrial Cancer Treatment T GuruFocus

Published: May 18, 2026, 10:39 p.m.
Merck’s TROP2 ADC opens global women’s cancer push with endometrial win - BioCentury

Merck’s TROP2 ADC opens global women’s cancer push with endometrial win BioCentury

Published: May 18, 2026, 10:04 p.m.
Sac-TMT Significantly Improves PFS/OS in Pretreated Endometrial Cancer - CancerNetwork

Sac-TMT Significantly Improves PFS/OS in Pretreated Endometrial Cancer CancerNetwork

Published: May 18, 2026, 7:33 p.m.
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Yahoo

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Yahoo

Published: May 18, 2026, 4:44 p.m.
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - Clinical Trials Arena

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial Clinical Trials Arena

Published: May 18, 2026, 4:34 p.m.
Merck, Kelun score with sac-TMT in endometrial cancer trial - Fierce Pharma

Merck, Kelun score with sac-TMT in endometrial cancer trial Fierce Pharma

Published: May 18, 2026, 3:21 p.m.
Merck announces trial results for ADC that addresses unmet needs for patients with advanced endometrial cancer - PharmaLive

Merck announces trial results for ADC that addresses unmet needs for patients with advanced endometrial cancer PharmaLive

Published: May 18, 2026, 1:38 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!